Lensar Gets FDA 510(k) Clearance for ALLY Adaptive Cataract Treatment System

By Chris Wack

Lensar Inc. received the U.S. Food and Drug Administration 510(k) clearance for its next-generation ALLY Adaptive Cataract Treatment System, the company said Monday.

The company plans to deliver the first ALLY Systems to surgeons in the third quarter of this year through a controlled and targeted initial launch. Following this launch, the company plans to make ALLY widely available to surgeons in 2023.

ALLY is the first FDA-cleared platform to enable cataract surgeons to complete the femtosecond-laser-assisted cataract surgery procedure seamlessly in a single, sterile environment, Lensar said.

Lensar shares were up 12%, to $7.24, in premarket trading.

Write to Chris Wack at [e-mail]

(END) Dow Jones Newswires

06-13-22 0725ET